Brief: Allovir Q2 EPS USD -0.48
03/08/2023 12:00
Aug 03 (Reuters) - Allovir Q2 operating income USD -47.304 million. * Q2 net income USD -45.267 million * Q2 operating expenses USD 47.304 million
Recent news on Kalaris Therapeutics
See all newsKalaris Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Kalaris Therapeutics Q2 net loss narrows on lower administrative costs
Kalaris Therapeutics Inc expected to post a loss of 49 cents a share - Earnings Preview
Kalaris Therapeutics posts smaller-than-expected Q1 net loss
Brief: Kalaris Therapeutics Inc Q1 Operating Income USD -11.833 Million